Zevra Therapeutics (ZVRA) EBIAT (2016 - 2025)
Historic EBIAT for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.
- Zevra Therapeutics' EBIAT rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13941.6%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
- Latest data reveals that Zevra Therapeutics reported EBIAT of -$544000.0 as of Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
- Zevra Therapeutics' 5-year EBIAT high stood at $74.7 million for Q2 2025, and its period low was -$35.7 million during Q4 2024.
- Its 5-year average for EBIAT is -$5.6 million, with a median of -$10.3 million in 2021.
- Per our database at Business Quant, Zevra Therapeutics' EBIAT skyrocketed by 62211.87% in 2021 and then crashed by 67438.79% in 2024.
- Zevra Therapeutics' EBIAT (Quarter) stood at -$2.7 million in 2021, then soared by 312.73% to $5.8 million in 2022, then crashed by 445.2% to -$19.8 million in 2023, then crashed by 80.05% to -$35.7 million in 2024, then skyrocketed by 98.48% to -$544000.0 in 2025.
- Its last three reported values are -$544000.0 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.